secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001437749-25-034819
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell Q3 product sales $5.5M (-8% YoY); net loss narrows to $140k; gross margin recovers to 43%
--------------------------------------------------------------------------------

- Product sales Q3 2025: $5.5M, down 8% YoY; nine-month 2025: $20.0M, up 7% YoY.
- Net loss Q3 2025: ($140k) or ($0.02)/share vs ($702k) loss in Q3 2024.
- Net income nine-month 2025: $1.8M ($0.20 diluted) vs ($2.7M) loss in prior period.
- Gross margin improved to 43% Q3 2025 vs 26% Q3 2024; nine-month 42.6% vs 27.3%.
- Adjusted EBITDA Q3: $751k vs $196k; nine-month: $4.4M vs $35k; cash $3.9M, no debt drawn.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000143774925034819/0001437749-25-034819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000143774925034819/iccc20251113_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-034819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer